Vision – The vision of the PRP is to increase the understanding of PD and to develop treatments
Parkinson’s disease (PD) is a degenerative movement disorder of the central nervous system resulting from a loss of neurons in a region of the brain called the substantia nigra. These neurons produce dopamine, a neurotransmitter important for motor control; however, as PD progresses, the death of dopaminergic neurons results in reduced dopamine levels and impairment of motor control.
For FY22, Congress transitioned the Neurotoxin Exposure Treatment Parkinson’s (NETP) program to the Parkinson’s Research Program (PRP) and broadened the research from neurotoxin exposure treatment PD research to all types of PD research. The PRP challenges the scientific community to develop the most impactful research that will advance the understanding of the disease, with the ultimate goal of ending PD.
For information on toxic exposure research, please go to the Toxic Exposures Research Program at CDMRP.
Dr. Angus Nairn Video
Yale University School of Medicine
Proteomic Methods for Analyzing Protein in Dopaminergic Neurons
Dr. Andrew Singleton Video
National Institute on Aging
Whole-Genome Sequencing in Parkinson’s
Dr. Kenneth Marek Video
Institute for Neurodegenerative Disorders
Evaluating the Natural History of Prodromal PD in the PARS Cohort
Dr. Caroline Tanner
University of California, San Francisco
Persistent Organic Pollutants and Parkinson’s disease in Native Populations of Hawaii and Alaska
Dr. Paul Greengard
New P11 Biomarker Predicts Clinical Effectiveness of Antidepressant Drugs
Dr. Howard J. Federoff
University of California, Irvine
PGC-1α Therapy for Parkinson Neurodegeneration
Last updated Sunday, December 31, 1600